Women Not Often Informed of Fertility Threat From Treatment

Swedish researchers have reported in the Journal of Clinical Oncology that men are far more likely to be informed of the risk of infertility posed by anti-cancer treatments than women, and that men are also more likely to be given information about options regarding fertility preservation.

The investigators, from the Karolinska Institute in Stockholm, reached their conclusions after receiving mailed questionnaires from 484 cancer survivors between the ages of 18 and 45. They found that four out of five men, or 80 percent, were informed that the chemotherapy regimen they were facing presented a threat to their fertility.

Meanwhile, only 48 percent of women said they were similarly informed. On top of that, just 14 percent of women said they were told about the options available for fertility preservation, compared to 68 percent of men.

Fertility preservation and the methods involved are much more complicated and much more expensive for women than they are for men. Researchers suggested that this helps to explain the disparity in the reported numbers, but hardly justifies it.

Of those that responded to the questionnaire, 54 percent of men went ahead and banked sperm to preserve some fertility. By way of comparison, just two percent of women underwent fertility preservation.

Researchers concluded, "There is an urgent need to develop fertility-related information adapted to female patients with cancer to improve their opportunities to participate in informed decisions regarding their treatment and future reproductive ability."

Source: JCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap